For most of the twentieth century, the idea that a gas could act as a signaling molecule inside the body was considered absurd. Then, in the late 1980s, three laboratories converged on the same unlikely answer — and rewrote the textbooks on vascular biology, wound healing, and cellular communication.
What it is: Nitric oxide (NO) is a tiny, short-lived gas molecule that cells use as a local signal — controlling blood vessel dilation, platelet behavior, wound repair, immune defense, and even certain kinds of memory formation.
Why researchers care: Because NO sits upstream of angiogenesis, vasodilation, fibroblast recruitment and gastric protection, a compound that nudges the NO pathway has a plausible mechanistic route to affecting many tissue-level outcomes at once.
Peptides studied for effects: BPC-157 is the primary example in the preclinical literature; angiogenic peptides like TB-500 (thymosin beta-4) and VEGF-derived fragments also intersect with NO biology.
Key caveat: NO measurements are always indirect — "NO pathway effects" in the peptide literature almost always mean downstream proxies (nitrite, cGMP, or pharmacological blockade with L-NAME), not NO itself.
Discovery of nitric oxide as a signaling molecule
In 1980, Robert Furchgott and John Zawadzki published a now-famous paper in Nature describing an unexpected observation. When they stripped the inner endothelial lining (the single-cell layer that lines blood vessels) from isolated rabbit aorta preparations, the blood vessels lost their ability to relax in response to acetylcholine. Something released by the endothelium — which they called endothelium-derived relaxing factor (EDRF) — was apparently required for the relaxation response (Furchgott & Zawadzki, 1980).
For nearly a decade, the chemical identity of EDRF remained contested. Then, in 1986, Furchgott and Louis Ignarro independently proposed that EDRF was in fact nitric oxide — a small, short-lived free radical gas (a molecule with an unpaired electron, making it highly reactive) (Ignarro et al., 1987). Salvador Moncada's group in London published converging biochemical evidence shortly afterward, demonstrating NO release from vascular endothelial cells (Palmer et al., 1987).
The finding that a gas could function as an intracellular and intercellular messenger overturned decades of assumptions in signaling biology. In 1998, Furchgott, Ignarro, and Ferid Murad shared the Nobel Prize in Physiology or Medicine for their work on nitric oxide as a signaling molecule in the cardiovascular system.
What is nitric oxide (NO)?
Nitric oxide is, chemically, one of the simplest molecules in biology: a single nitrogen atom bonded to a single oxygen atom, with one unpaired electron that makes it a free radical. It exists as a gas at physiological temperatures and dissolves freely in both aqueous and lipid phases, which lets it diffuse across cell membranes without any transporter.
- Small gaseous signaling molecule — at roughly 30 daltons, it is among the smallest biological messengers known.
- Short half-life in vivo — on the order of seconds, because NO reacts rapidly with oxygen, superoxide, and heme-containing proteins.
- Synthesized by NO synthases — a family of enzymes that convert L-arginine into L-citrulline, releasing NO as a by-product.
The short half-life is not a design flaw — it is the feature. A signal that dissipates in seconds cannot travel far, which makes NO an ideal local messenger for communication between adjacent cells within a tissue (Moncada et al., 1991).
The NO pathway in detail
The canonical nitric oxide signaling cascade can be described in five steps. Each is an enzyme-mediated event, and each has been characterized in substantial biochemical detail.
L-arginine as substrate
The starting material is the amino acid L-arginine. All mammalian NO synthesis begins with the oxidation of one of L-arginine's two guanidinium nitrogens. The reaction consumes molecular oxygen and NADPH, yielding L-citrulline and nitric oxide in stoichiometric amounts.
The NOS enzyme family
Three isoforms of nitric oxide synthase exist in mammals, encoded by three separate genes:
- nNOS (neuronal NOS, NOS1) — constitutively expressed in neurons and skeletal muscle; calcium-dependent; produces NO at low levels as a rapid neuromodulator.
- iNOS (inducible NOS, NOS2) — expressed after stimulation by cytokines or bacterial products; calcium-independent; produces larger, sustained amounts of NO as part of innate immune defense.
- eNOS (endothelial NOS, NOS3) — constitutively expressed in vascular endothelium; calcium-dependent; the principal source of NO that regulates vascular tone (Alderton et al., 2001).
Guanylate cyclase activation
Once released, NO diffuses into nearby cells and binds the heme iron at the active site of soluble guanylate cyclase (sGC). Binding induces a conformational change that dramatically increases the enzyme's catalytic activity — by several hundred fold. Soluble guanylate cyclase is, in effect, a purpose-built NO receptor (Denninger & Marletta, 1999).
cGMP as second messenger
Activated sGC converts GTP into cyclic guanosine monophosphate (cGMP), which accumulates rapidly in the cytoplasm. cGMP is the second messenger that mediates most of NO's downstream biological effects. It is removed by phosphodiesterases — notably PDE5 in vascular smooth muscle, the target of sildenafil.
Protein kinase G activation
Elevated cGMP activates cGMP-dependent protein kinase (PKG), which phosphorylates a range of downstream targets including IP3 receptors, myosin light chain phosphatase, and several ion channels. The net effect in vascular smooth muscle is relaxation; in platelets, inhibition of aggregation; in neurons, modulation of synaptic activity.
L-arginine → NOS enzyme → NO gas → diffusion → soluble guanylate cyclase → cGMP → PKG → downstream effects. Each step is an established, well-characterized biochemical event. The full cascade runs in seconds.
Biological roles
Once nitric oxide's role as a signaling molecule was established, investigators rapidly found it implicated in physiological systems throughout the body. The range is unusually broad.
Vascular function
Endothelial NO is the principal mediator of vasodilation (blood vessel widening) in most vascular beds. Loss of endothelial NO production — a state called "endothelial dysfunction" — is one of the earliest measurable abnormalities in atherosclerosis and hypertension (Vanhoutte et al., 2017).
Wound healing and tissue repair
NO plays multiple, sometimes opposing roles across the phases of wound healing. Early after injury, iNOS-derived NO participates in inflammation and pathogen defense. Later, eNOS-derived NO supports angiogenesis, fibroblast proliferation, and collagen deposition. Mice lacking iNOS show delayed cutaneous wound closure; mice lacking eNOS show impaired angiogenic responses (Witte & Barbul, 2002).
Angiogenesis
NO is required for the sprouting and migration of new blood vessels (angiogenesis — new blood vessel formation from existing ones) in response to vascular endothelial growth factor (VEGF). Pharmacological inhibition of NOS blocks VEGF-induced angiogenesis in multiple models, placing NO downstream of many pro-angiogenic signals (Cooke, 2003).
Immune function
Macrophages activated by bacterial lipopolysaccharide or interferon-gamma upregulate iNOS and release NO at cytotoxic concentrations, which contributes to killing intracellular pathogens. The same chemistry, unregulated, contributes to tissue damage in sepsis and chronic inflammation.
Neurotransmission
In the central nervous system, nNOS-derived NO acts as a retrograde messenger at glutamatergic synapses, contributing to long-term potentiation in the hippocampus and to activity-dependent synaptic plasticity more broadly.
Gastric mucosal protection
NO is one of several factors maintaining the integrity of the gastric mucosal barrier. Pharmacological NOS inhibition sensitizes the stomach to injury from ethanol, NSAIDs, and stress, a finding that has been exploited in hundreds of preclinical gastric injury studies (Whittle, 1995).
Peptides studied for NO pathway effects
Because the NO pathway sits at the intersection of vascular biology, tissue repair, and inflammation, it has become a focal point for researchers studying peptides with reported tissue-modeling effects. The peptides that most often appear in the NO-pathway literature are those whose observed actions map plausibly onto NO biology.
BPC-157
The pentadecapeptide BPC-157 has been studied by Sikiric and colleagues for its interactions with the NO system for over two decades. Published experiments in rat models report that many of the peptide's protective effects against gastric injury, vascular occlusion, and tissue damage are attenuated by co-administration of L-NAME (a non-selective NOS inhibitor) and restored by L-arginine (Sikiric et al., 2014). The group has described this interaction as "protection against NO blockade" and has proposed NO pathway modulation as a unifying mechanistic hypothesis (Sikiric et al., 2018).
Angiogenic peptides
A broader class of peptides — including VEGF-derived fragments and thymosin beta-4 (TB-500) — is studied for pro-angiogenic effects that intersect with NO biology, since angiogenesis in most models is partially NO-dependent (Smart et al., 2007).
The statement "researchers study peptide X for its effects on the NO pathway" is descriptive. It reflects what is in the peer-reviewed literature. It is not a claim about human efficacy, and it is not a recommendation for human use. The compounds discussed here are research chemicals. Their study in animal models is a matter of scientific record; their use in humans is neither approved nor endorsed.
Key research areas
Vascular biology
The vascular biology literature on NO is vast. The definitive review by Moncada, Palmer, and Higgs in Pharmacological Reviews remains the starting point for most students of the field; it synthesizes the first decade of NO research and maps the core biochemistry and physiology that subsequent work has built upon (Moncada et al., 1991).
Gastric protection
Sikiric and colleagues at the University of Zagreb developed much of the modern literature on gastric cytoprotection and its relationship to NO. Their experimental paradigm — inducing gastric injury, blocking NOS with L-NAME, and examining how candidate agents restore protection — has been applied to dozens of compounds and to hundreds of injury models (Sikiric et al., 2012).
Wound healing
Beyond the gastric mucosa, a body of work by Schaffer, Efron, and Barbul has examined NO's role in cutaneous wound healing, measuring nitrate/nitrite accumulation at wound sites and characterizing the phenotype of NOS-deficient mice in standard wound models (Schaffer et al., 1997).
Tendon repair
A smaller literature has examined NO signaling in tendon healing. Murrell and colleagues published a series of papers demonstrating that NOS expression is upregulated after experimental tendon injury and that NOS inhibition impairs healing in rat Achilles tendon models (Murrell et al., 1997).
Why peptide researchers care about NO
The NO pathway is appealing to peptide researchers for a specific reason: it is upstream of many of the tissue processes they want to measure. Angiogenesis, vasodilation, fibroblast recruitment, collagen deposition, and inflammatory resolution are all downstream of, or partially dependent on, NO signaling. A compound that modulates NO — whether by upregulating NOS expression, protecting against NOS inhibition, or altering cGMP dynamics — has a plausible mechanistic route to affecting many tissue outcomes at once.
This is also why the NO pathway acts as something of a "stress test" in preclinical experiments. If a candidate peptide's protective effect against injury is abolished by L-NAME (a drug that blocks NO synthesis) and restored by L-arginine (the amino acid starting material for NO), investigators infer that NO is somewhere in the causal chain. If the effect persists unchanged under NOS blockade, investigators infer a NO-independent mechanism. The L-NAME/L-arginine paradigm is a simple, fast, and widely used way to generate mechanistic hypotheses (Sikiric et al., 2014).
Methods for measuring NO activity
Because NO itself is so short-lived, investigators rarely measure the molecule directly. Instead they measure stable end-products, downstream second messengers, or enzymatic precursors. The most common techniques include:
- Griess reaction — a century-old colorimetric assay that detects nitrite (NO2−), the stable oxidation product of NO in aqueous solution. Simple, cheap, and widely used for bulk tissue measurements (Green et al., 1982).
- DAF-FM diacetate — a fluorescent probe that reacts with NO to yield a stable fluorescent triazole. Suitable for live-cell imaging and microscopy.
- Electron paramagnetic resonance (EPR) — the only technique that directly detects NO via its unpaired electron, typically using iron-based spin traps. Technically demanding but mechanistically definitive.
- cGMP immunoassays — measure the second messenger rather than NO itself. A functional readout of activation of the canonical pathway.
- NOS activity assay — measures the conversion of radiolabelled L-arginine to L-citrulline in tissue homogenates, providing an enzymatic rate rather than a concentration.
- Western blot for NOS isoforms — quantifies protein abundance of eNOS, iNOS, or nNOS, useful for studying expression changes over time.
In the peptide literature, the Griess reaction and NOS pharmacological blockade (L-NAME) remain the two most common experimental tools. Neither is perfect; both are tractable; together they form the backbone of the NO-pathway phenotyping used in preclinical studies (Bryan & Grisham, 2007).
Every NO assay is indirect in some way. Griess measures nitrite, not NO. cGMP measures downstream signaling, not the molecule itself. EPR can see NO but only in specialized conditions. The practical consequence is that "NO pathway effects" reported in the peptide literature should always be read with attention to which assay was used and what it actually measured.